I'm Jim Kramer and you're about to hear a sample taken directly from today's

CBC Investing Club morning meeting.

I went to Larry Williams one of my favorite technicians saying, okay, listen, we're in March.

That's when you said things are better.

Now I do believe, by the way, as we get oversold, we're going to get, it's interesting.

And Lowe's was interesting.

It was down, Proctor down on a major upgrade.

Yeah, very surprising.

Very surprising.

And I think that I'm not willing to say it's an opportunity because we own a lot and because I look at the 10-year and I say they're not going to let you buy Proctor if the 10-year keeps going higher and yield and lower the price.

Meanwhile, Eli Lilly did something on it. I can posit what they did. They cut the price of insulin.

Okay. Now, let's just say if you wanted to introduce a major Alzheimer's drug that costs a fortune,

you might be able to cover yourself with

Gloria by saying, listen, hey, we took the insulin hit. Now let us have our Alzheimer's. Now, I know

from my work with the American Brain Foundation and the American Migrant Foundation that there is a

belief that if there's going to be a drug that's going to be good, it might be Eli Lilly's.

But Eli Lilly will not confirm anything to me, CFO CEOs. And that's keep in mind, too, while they do sell some insulin products, Lilly is known for its diabetes franchise.

It's not insulin that's the driver of the story.

It's more of these drugs, whether it's Trulicity, Manjaro, two, drugs that reduce A1C.

Holy Grail, Majaro will have to take it for the rest of your life.

You start it, you gotta take it.

Yeah.

...